Urotensin II increases foam cell formation by repressing ABCA1 expression through the ERK/NF-κB pathway in THP-1 macrophages

被引:25
作者
Wang, Yan [1 ]
Wu, Jian-Feng [3 ]
Tang, Yan-Yan [2 ]
Zhang, Min [2 ]
Li, Yuan [2 ]
Chen, Kong [3 ]
Zeng, Meng-Ya [3 ]
Yao, Feng [2 ]
Xie, Wei [2 ]
Zheng, Xi-Long [4 ]
Zeng, Gao-Feng [3 ]
Tang, Chao-Ke [2 ]
机构
[1] Univ South China, Affiliated Hosp 2, Dept Anesthesiol, Hengyang 421001, Hunan, Peoples R China
[2] Univ South China, Key Lab Atherosclerol Hunan Prov, Inst Cardiovasc Res, Hengyang 421001, Hunan, Peoples R China
[3] Univ South China, Affiliated Hosp 2, Dept Cardiovasc Med, Hengyang 421001, Hunan, Peoples R China
[4] Univ Calgary, Dept Biochem & Mol Biol, Libin Cardiovasc Inst Alberta, Hlth Sci Ctr, Calgary, AB T2N 4N1, Canada
关键词
Urotensin II; ERK; NF-kappa B; ABCA1; Cholesterol efflux; CASSETTE-TRANSPORTER A1; LIVER X RECEPTOR; CHOLESTEROL EFFLUX; SIGNALING PATHWAY; ATHEROSCLEROSIS; VASOCONSTRICTOR; HDL; PROLIFERATION; SUPPRESSES; DISEASE;
D O I
10.1016/j.bbrc.2014.09.030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objective: Foam cell formation in the arterial wall plays a key role in the development of atherosclerosis. Recent studies showed that Urotensin II (U II) is involved in the pathogenesis of atherosclerosis. Here we examined the effects of human U II on ATP-binding cassette transporter A1 (ABCA1) expression and the underlying mechanism in THP-1 macrophages. Methods and results: Cultured THP-1 macrophages were treated with U II, followed by measuring the intracellular lipid contents, cholesterol efflux and ABCA1 levels. The results showed that U II dramatically decreased ABCA1 levels and impaired cholesterol efflux. However, the effects of U II on ABCA1 protein expression and cellular cholesterol efflux were partially reversed by inhibition of extracellular signal regulated kinase 1/2 (ERK1/2) and nuclear factor kappa B (NF-kappa B) activity, suggesting the potential roles of ERK1/2 and NF-kappa B in ABCA1 expression, respectively. Conclusion: Our current data indicate that U II may have promoting effects on the progression of atherosclerosis, likely through suppressing ABCA1 expression via activation of the ERK/NF-kappa B pathway and reducing cholesterol efflux to promote macrophage foam cell formation. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:998 / 1003
页数:6
相关论文
共 35 条
[1]   Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages [J].
Aiello, RJ ;
Brees, D ;
Bourassa, PA ;
Royer, L ;
Lindsey, S ;
Coskran, T ;
Haghpassand, M ;
Francone, OL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) :630-637
[2]   Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease [J].
Al Kindi, Hamood ;
Hafiane, Anouar ;
You, Zhipeng ;
Albanese, Isabella ;
Pilote, Louise ;
Genest, Jacques ;
Schwertani, Adel .
PEPTIDES, 2014, 55 :151-157
[3]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[4]   ATHEROSCLEROTIC PLAQUE REDUCTION: BLOOD PRESSURE, DYSLIPIDEMIA, ATHEROTHROMBOSIS [J].
Arora, Satish ;
Nicholls, Stephen J. .
DRUGS OF TODAY, 2008, 44 (09) :711-718
[5]   Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta [J].
Bousette, N ;
Patel, L ;
Douglas, SA ;
Ohlstein, EH ;
Giaid, A .
ATHEROSCLEROSIS, 2004, 176 (01) :117-123
[6]   Retinoic acid receptor-mediated induction of ABCA1 in macrophages [J].
Costet, P ;
Lalanne, F ;
Gerbod-Giannone, MC ;
Molina, JR ;
Fu, X ;
Lund, EG ;
Gudas, LJ ;
Tall, AR .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (21) :7756-7766
[7]   Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease [J].
Douglas, SA ;
Ohlstein, EH .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) :229-237
[8]   Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey [J].
Douglas, SA ;
Sulpizio, AC ;
Piercy, V ;
Sarau, HM ;
Ames, RS ;
Aiyar, NV ;
Ohlstein, EH ;
Willette, RN .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) :1262-1274
[9]   Update on strategies to increase HDL quantity and function [J].
Duffy, Danielle ;
Rader, Daniel J. .
NATURE REVIEWS CARDIOLOGY, 2009, 6 (07) :455-463
[10]   IFN-γ down-regulates ABCA1 expression by inhibiting LXRα in a JAK/STAT signaling pathway-dependent manner [J].
Hao, Xin-rui ;
Cao, Dong-li ;
Hu, Yan-wei ;
Li, Xiao-xu ;
Liu, Xie-hong ;
Xiao, Ji ;
Liao, Duan-fang ;
Xiang, Jim ;
Tang, Chao-ke .
ATHEROSCLEROSIS, 2009, 203 (02) :417-428